Quest Diagnostics Incorporated (DGX)
| Market Cap | 27.71B +42.5% |
| Revenue (ttm) | 11.84B +9.1% |
| Net Income | 1.13B +16.5% |
| EPS | 10.04 +17.9% |
| Shares Out | 110.02M |
| PE Ratio | 25.09 |
| Forward PE | 21.71 |
| Dividend | $3.44 (1.37%) |
| Ex-Dividend Date | Oct 6, 2026 |
| Volume | 919,589 |
| Open | 255.14 |
| Previous Close | 252.92 |
| Day's Range | 250.95 - 256.99 |
| 52-Week Range | 171.18 - 256.99 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | 257.27 (+2.16%) |
| Earnings Date | Oct 22, 2026 |
About DGX
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceu... [Read more]
Financial Performance
In 2025, Quest Diagnostics's revenue was $11.04 billion, an increase of 11.78% compared to the previous year's $9.87 billion. Earnings were $988.00 million, an increase of 14.09%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for DGX stock is "Buy." The 12-month stock price target is $257.27, which is an increase of 2.16% from the latest price.
News
The big winners of the tech wreck are biopharma stocks
Who would have believed that the boring healthcare industry would be the hottest stock sector of 2026? Companies like Johnson & Johnson, Quest Diagnostics and UnitedHealth Group have long been known f...
Lab testing giant Quest Diagnostics confirms patients' personal and health data was compromised during breach
Medical lab testing giant Quest Diagnostics has confirmed a cyberattack and data breach affecting an as-yet unspecified amount of sensitive patient information stored in its systems, according to a le...
Quest Diagnostics price target raised to $262 from $260 at Baird
Baird analyst Eric Coldwell raised the firm’s price target on Quest Diagnostics (DGX) to $262 from $260 and keeps a Neutral rating on the shares. The firm updated its model…
Quest Diagnostics price target raised to $262 from $260 at Baird
Baird analyst Eric Coldwell raised the firm’s price target on Quest Diagnostics (DGX) to $262 from $260 and keeps a Neutral rating on the shares. The firm updated its model…
Quest Diagnostics discloses breach after ‘unauthorized access’
Quest Diagnostics (DGX) is fractionally down in morning trading after the company said in a regulatory filing that on October 21, it learned of unauthorized access to its Quanum LSM…
Quest Diagnostics Earnings Call Transcript: Q3 2026
Q3 revenue rose 10% and adjusted EPS increased 15.4%, prompting higher FY2026 guidance. Strong organic demand and productivity gains were tempered by expected PAMA cuts, while consumer growth and new testing initiatives expand opportunities.
Quest Diagnostics Earnings release: Q3 2026
Quest Diagnostics released its Q3 2026 earnings on October 22, 2026, summarizing the period's financial results.
Quest Diagnostics Slides: Q3 2026
Quest Diagnostics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 22, 2026.
Quest Diagnostics Quarterly report: Q3 2026
Quest Diagnostics has published its Q3 2026 quarterly earnings report on October 22, 2026.
Quest Diagnostics ups FY26 adjusted EPS view to $11.25-$11.35 from $11.05-$11.25
Consensus $11.20. Raises FY26 revenue view to $12.07B-$12.11B from $11.95B-$12.05B, consensus $12.02B. Backs FY26 capital expenditures view $550M.
Quest Diagnostics reports Q3 adjusted EPS $3.00, consensus $2.87
Reports Q3 revenue $3.1B, consensus $3.05B. “We delivered revenue growth of 10% and adjusted EPS growth of over 15% on continued strength across our physician, hospital and consumer channels, compleme...
Quest Diagnostics Reports Third Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
Third quarter revenues of $3.10 billion, up 10.0% from 2025, on strong organic revenue growth Third quarter reported diluted earnings per share ("EPS") of $2.78, up 28.7% from 2025; and adjusted dilut...
Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option
Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027 First and only FDA-...
A new at-home HPV test kit is going national through Quest Diagnostics
Patients across the U.S. will soon have access to a new cervical cancer test collected from the comfort of their own home—no stirrups, speculum, or in-person doctor's visit needed.
Quest Diagnostics price target raised to $250 from $245 at UBS
UBS raised the firm’s price target on Quest Diagnostics (DGX) to $250 from $245 and keeps a Neutral rating on the shares.
Current Screening Thresholds May Miss Half of Patients with Primary Aldosterone, a Leading Cause of Severe High Blood Pressure, Finds Study in Hypertension
Half of patients with the hormonal disorder, which raises risk of heart attack, stroke and kidney disease, may be undiagnosed under current screening thresholds SECAUCUS, N.J., Oct. 19, 2026 /PRNewswi...
Big tech is wobbling. Goldman Sachs says it's time to buy these 23 unloved stocks instead.
Goldman Sachs says consumer-facing laggard stocks are the best way forward as earnings growth is set to slow next year and big tech stocks struggle.
Quest Diagnostics price target raised to $260 from $250 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Quest Diagnostics (DGX) to $260 from $250 and keeps an Overweight rating on the shares. The firm adjusted targets in…
Quest Diagnostics’ Haystack MRD shows efficacy in colorectal cancer detection
Quest Diagnostics (DGX) announced that a new study published in The Journal of Molecular Diagnostics showed that Quest’s Haystack MRD test is highly accurate at detecting residual and recurrent diseas...
Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials
Test showed 100% specificity, with no false-positive results in the cohort, at both 3- and 5-year follow-up, and sensitivity of 100% and 83.3%, respectively, for predicting disease recurrence SECAUCUS...
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
SECAUCUS, N.J., Sept. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its third quarter 2026 finan...
Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
Study published in JAMA Network Open of over 193,000 patients nationwide reveals that individuals with evidence of exposure to Borrelia burgdorferi, the bacterium that causes Lyme disease, are more th...
Quest Diagnostics price target raised to $260 from $250 at Truist
Truist raised the firm’s price target on Quest Diagnostics (DGX) to $260 from $250 and keeps a Hold rating on the shares as part of a broader research note updating…
Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics
75% of registered voters surveyed call diagnostic testing "very important" to their care, and a bipartisan majority wants Congress to pass the RESULTS Act before additional Medicare cuts are schedule...
Quest Diagnostics Transcript: 2026 Global Healthcare Conference
Revenue and earnings growth have outpaced long-term plans, driven by organic expansion, partnerships, and a rapidly growing consumer health segment. Strategic focus has shifted from M&A to integration and partnerships, with new executive talent and board expertise supporting this evolution. Regulatory uncertainty around PAMA remains, but advocacy for legislative solutions continues.